Top

Published in:

01-04-2009 | Short Communication

Skin and oral lesions associated to imatinib mesylate therapy

Authors: Fernanda Gonçalves Basso, Camila Cominato Boer, Maria Elvira Pizzigatti Corrêa, Marcia Torrezan, Maria Letícia Cintra, Marina H. C. Gallottini de Magalhães, Paulo da Silva Santos, Cármino Antônio de Souza

Published in: Supportive Care in Cancer | Issue 4/2009

Abstract

Introduction

Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects.

Results and discussion

Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph⁺ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.

Carella AM, Frassoni F, Melo J et al (1997) New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 82:478–495PubMed

Mahapatra M, Mishra P, Kumar R (2007) Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol 86:537–538 doi:10.1007/s00277-007-0265-y PubMedCrossRef

Breccia M, Carmosino I, Russo E et al (2005) Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 74:121–123 doi:10.1111/j.1600-0609.2004.00351.x PubMedCrossRef

Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037 doi:10.1056/NEJM200104053441401 PubMedCrossRef

Severino G, Chillotti C, De Lisa R et al (2005) Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 39:162–164 doi:10.1345/aph.1E127 PubMed

O’Brien SG, Deininger MW (2003) Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 40(Suppl 2):26–30 doi:10.1016/S0037-1963(03)70017-1 PubMedCrossRef

van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423 doi:10.1016/S0140-6736(01)06535-7 PubMedCrossRef

Brouard M, Saurat JH (2001) Cutaneous reactions to STI571. N Engl J Med 345:618–619 doi:10.1056/NEJM200108233450814 PubMedCrossRef

Lim DS, Muir J (2002) Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 205:169–171 doi:10.1159/000063899 PubMedCrossRef

10.

Pascual JC, Matarredona J, Miralles J et al (2006) Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 45:1471–1473 doi:10.1111/j.1365-4632.2006.03171.x PubMedCrossRef

11.

Chainani-Wu N, Lozada-Nur F, Terrault N (2004) Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:171–183 doi:10.1016/j.tripleo.2003.11.010 PubMedCrossRef

12.

Cunha KS, Manso AC, Cardoso AS et al (2005) Prevalence of oral lichen planus in Brazilian patients with HCV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:330–333 doi:10.1016/j.tripleo.2004.11.017 PubMedCrossRef

13.

Lodi G, Giuliani M, Majorana A et al (2004) Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 151:1172–1181 doi:10.1111/j.1365-2133.2004.06257.x PubMedCrossRef

Title: Skin and oral lesions associated to imatinib mesylate therapy
Authors: Fernanda Gonçalves Basso
Camila Cominato Boer
Maria Elvira Pizzigatti Corrêa
Marcia Torrezan
Maria Letícia Cintra
Marina H. C. Gallottini de Magalhães
Paulo da Silva Santos
Cármino Antônio de Souza
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 4/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0536-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Results and discussion

Please log in to get access to this content

Other articles of this Issue 4/2009

Comprehensive analysis of cancer coverage in important Chinese newspapers between 2000 and 2007

Development and evaluation of a problem-focused psychosocial intervention for patients with head and neck cancer

It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting

“I was never like that”: Australian findings on the psychological and psychiatric sequelae of corticosteroids in haematology treatments

Professional relationships in palliative care decision making

Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings

Keynote webinar | Spotlight on antibody–drug conjugates in cancer